Medicare AdvantagePrior AuthMedium impact
Beleodaq® (belinostat) (Revised)
Humana·FL, KY, SC · Oncology, Hematology·Medicaid
Effective date
Nov 26, 2025
We identified it
Aug 12, 2026
Summary
This is a revised Humana prior authorization policy for Beleodaq (belinostat) for relapsed or refractory peripheral T-cell lymphoma (PTCL), updated November 26, 2025. The policy requires prior authorization for all new and renewal requests, with approval duration of 6 months. Key exclusions include patients with disease progression on Beleodaq and those on concomitant HDAC inhibitor therapy (Istodax, Zolinza, Folotyn).
Action Required
By December 26, 2025: Billing and clinical teams must implement prior authorization requirements for all Beleodaq (belinostat) IV infusions under Humana Medicare, Medicaid-Florida, Medicaid-Kentucky, and Medicaid-South Carolina plans. Update billing system to flag all J9018 claims requiring prior auth submission before claims processing. Verify patient eligibility against inclusion criteria (relapsed or refractory PTCL diagnosis) and exclusion criteria (no prior disease progression on Beleodaq, no concomitant Istodax/Zolinza/Folotyn therapy). Ensure providers document absolute neutrophil count >1.0 x 10^9/L and platelet count ≥50 x 10^9/L prior to each cycle initiation. Configure system to approve initial and renewal authorizations for 6-month periods. Claims submitted without prior authorization will be denied. Train oncology billing staff on new requirements and provide them with access to the full policy at www.humana.com/PAL.